
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Sorrento Therape (SRNE) is a leading biotechnology business with stocks listed in the US. It opened the day at US$2.01 after a previous close of US$2.01. During the day the price has varied from a low of USD2 to a high of USD2.2. The latest price was USD2.15 (25 minute delay). Sorrento Therape is listed on the NASDAQ. All prices are listed in US Dollars.
How to buy shares in Sorrento Therape
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for Sorrento Therape. Find the share by name or ticker symbol: SRNE. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sorrento Therape reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$2.01, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of Sorrento Therape, depending on your broker.
- Check in on your investment. Congratulations, you own a part of Sorrento Therape. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
Our top pick for
US stocks

Our top pick for
Overall broker

Our top pick for
Low-cost broker

What's in this guide?
- Sorrento Therape key stats
- Compare share trading platforms
- Is Sorrento Therape stock a buy or sell?
- Sorrento Therape performance over time
- Sorrento Therape's financials
- How volatile are Sorrento Therape shares?
- Does Sorrento Therape pay a dividend?
- Have Sorrento Therape shares ever split?
- Other common questions
Sorrento Therape stock price (NASDAQ:SRNE)
Use our graph to track the performance of SRNE stocks over time.Sorrento Therape shares at a glance
Open | US$2.01 |
---|---|
High | US$2.2 |
Low | US$2 |
Close | US$2.15 |
Previous close | US$2.01 |
Change | US$0.14 |
Change % | 6.9652% |
Volume | 9,729,508 |
52-week range | US$1.15 - US$11.07 |
---|---|
50-day moving average | US$1.646 |
200-day moving average | US$4.0832 |
Target price | US$21 |
PE ratio | N/A |
Dividend yield | US$0 (0%) |
Earnings per share (TTM) | US$-1.527 |
Compare trading apps to buy Sorrento Therape shares
Is it a good time to buy Sorrento Therape stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. However, this is not a recommendation. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Use the fields above to explore the returns from a historical investment. Please refer to the charts further up this page to see performance over 5 years, or other periods. Past performance doesn't indicate future results. Capital is at risk.
Sorrento Therape price performance over time
Historical closes compared with the last close of $2.15
1 week (2022-06-23) | -5.70% |
---|---|
1 month (2022-06-03) | 25.73% |
6 months (2021-12-31) | -53.76% |
1 year (2021-07-02) | -77.96% |
---|---|
2 years (2020-07-02) | -68.61% |
3 years (2019-07-03) | -13.65% |
5 years (2017-07-03) | 13.16% |
Stocks similar to Sorrento Therape
Sorrento Therape financials
Revenue TTM | US$57 million |
---|---|
Gross profit TTM | US$-167,049,000 |
Return on assets TTM | -32.96% |
Return on equity TTM | -206.57% |
Profit margin | 0% |
Book value | 0.616 |
Market capitalisation | US$805.1 million |
TTM: trailing 12 months
Sorrento Therape share dividends
We're not expecting Sorrento Therape to pay a dividend over the next 12 months.
Have Sorrento Therape's shares ever split?
Sorrento Therape's shares were split on a 1:25 basis on 1 August 2013. So if you had owned 25 shares the day before the split, the next day you would own 1 share. This wouldn't directly have changed the overall worth of your Sorrento Therape shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for Sorrento Therape shares which in turn could have impacted Sorrento Therape's share price.
Sorrento Therape share price volatility
Over the last 12 months, Sorrento Therape's shares have ranged in value from as little as US$1.15 up to US$11.07. A popular way to gauge a stock's volatility is its "beta".
Beta measures a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sorrento Therape's is 2.4288. This would suggest that Sorrento Therape's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Sorrento Therape overview
Sorrento Therapeutics, Inc., a clinical stage and commercial biopharmaceutical company, develops therapies for cancer, autoimmune, inflammatory, viral, and neurodegenerative diseases. It operates through two segments, Sorrento Therapeutics and Scilex. The company provides cancer therapeutic by leveraging its proprietary G-MAB antibody library and targeted delivery modalities, which include chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, and antibody drug conjugate, as well as bispecific antibody approach; and Sofusa, a drug delivery technology that deliver biologic directly into the lymphatic system. Its clinical programs in development include anti-CD38 CAR-T therapy for the treatment of multiple myeloma, as well as for amyloidosis and graft versus host disease. The company develops resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin for late stage cancer and osteoarthritis knee pain treatment; and ZTlido, a lidocaine delivery system for the treatment of postherpetic neuralgia. It engages in the development of SEMDEXA, an injectable viscous gel formulation, which is Phase III trial for the treatment of sciatica, a pathology of low back pain; SP-103, an investigational non-aqueous lidocaine topical system undergoing clinical development in chronic low back pain condition; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for the treatment of fibromyalgia. It has collaboration with SmartPharm Therapeutics Inc. to develop gene-encoded antibody vaccine to protect against COVID-19; Celularity, Inc. for initiating Phase I/II clinical study, including up to 94 patients with COVID-19; Mount Sinai Health System to develop COVI-SHIELD, an antibody therapy targeting SARS-CoV-2 infection; and Mayo Clinic for Phase Ib pilot study using sofusa lymphatic drug delivery technology to deliver Ipilimumab in patient with melanoma. The company was founded in 2006 and is based in San Diego, California.
Sorrento Therape in the news
Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji
Sorrento Therapeutics, Inc. announces the appointment of the Honorable Tommy G. Thompson, as Covid-19 Special Consultant to Chairman and CEO Henry Ji
Scilex Holding Company, a Sorrento Company, enters into an agreement for an exclusive license with ROMEG Therapeutics, LLC, for the right to commercialize Gloperba®, an FDA-approved prophylactic treatment for painful gout flares in adults, in the US.
Frequently asked questions
More guides on Finder
-
How to invest in the Octava Minerals IPO
Everything we know about the Octava Minerals IPO, plus information on how to buy in.
-
How to invest in the Australia Sunny Glass Group IPO
Everything we know about the Australia Sunny Glass Group IPO, plus information on how to buy in.
-
How to buy Kincora Copper (KCC) shares
Steps to owning and managing Kincora Copper shares.
-
How to invest in the Dragon Mountain Gold IPO
Everything we know about the Dragon Mountain Gold IPO, plus information on how to buy in.
-
How to buy Arcadia Minerals (AM7) shares
Steps to owning and managing Arcadia Minerals shares.
-
How to buy Nexgen Energy (NXG) shares
Steps to owning and managing Nexgen Energy shares.
-
How to buy Keypath Education (KED) shares
Steps to owning and managing Keypath Education shares.
-
What are green bonds and how do they impact the world?
If you want to directly fund climate solutions a green bond is a great place to start. Here is how they work.
-
5 best ways to invest money in Australia in 2022
What's the best way to invest money in Australia? Find out about robo advisors, index funds, cryptocurrency and more in this guide.
-
How to buy EBR Systems (EBR) shares
Steps to owning and managing EBR Systems shares.
Ask an Expert